About
BioCanRx accelerates the development of cancer immunotherapies by funding and supporting translational research — the stage that bridges lab discoveries and real-world patient treatments.
With a model tailor-made for Canada’s health research system, we ensure our public funded research delivers true patient benefit and strengthens the life sciences economy.
Why BioCanRx?
Canada’s Collaborative Cancer Immunotherapy Network
Scientists
Clinicians
Academic and institutional partners
Industry leaders
Patient groups and non-profits
Policymakers and health system partners
By working together, we accelerate the development of cutting-edge immune oncology therapies for patients in Canada.
The Valley of Death – Bridging the Translational Gap
Canada excels at medical discovery but often struggles to translate breakthroughs into treatments. Cancer researchers face funding gaps — the “valley of death” — that can delay or halt clinical progress.
BioCanRx bridges this gap by funding translational research, supporting clinical trial readiness, and ensuring promising therapies move forward efficiently.
BioCanRx’s investments have led to clinical trials that benefit patients, built a strong pipeline of Canadian researchers, and strengthened Canada’s position in the global life sciences sector.
Funding
Results
Progress
Trials
How We Work
Model Tailor-made for Canada’s Health Research Enterprise
Our approach is milestone-driven and outcomes-focused. By embedding regulatory, GMP manufacturing, and clinical planning from the start, BioCanRx ensures innovations are not only scientifically robust but also safe, scalable, and patient-ready.
1. Research
Funding milestone-driven projects.
2. Training
Developing the next generation of scientific and clinical talent.
3. Manufacturing
Supporting GMP biomanufacturing capacity across Canada.
Translational Cancer Research Capacity-building Engine for Immunotherapy Development
We drive cancer immunotherapy from discovery to treatment by funding the translational stage, where science becomes impact. Our integrated model supports research, training, and manufacturing to build national capacity, accelerate timelines, and get results.
1. Pipeline investment model supporting integrated bench-to-bedside translational acitivites
2. Cross-cutting investments to improve translational science and support sustainable health system adoption for Canadian health care systems
3. Access to expertise and skill sets necessary to support translational research
4. Knowledge exchange, technology transfer, advice and mentorhsip to suppport translational resarch
5. Translational research training linked to translational research projects to build up Canadian capacity
6. Patient groups engaged in advisory roles on the overall direction of the resarch program, policy gaps and patient partner training
7. Science, Technology and Innovation partnership development to support the translational research program and health system adoption
Strengthening Canada's Health and Research Future
For more than 10 years BioCanRx has been supporting translational research in immunotherapy for cancer in Canada. Our investments have benefited researchers, supported the development and delivery of new therapies to clinic, and resulted in significant benefits for both the life sciences economy and patients in Canada.
Our Partnerships
Building Bridges Across Research and Industry
BioCanRx partners with industry, academia, institutions, and non-profits to accelerate immunotherapy development and access to innovative treatments for patients in Canada. From research to commercialization, our investment model supports collaboration to drive impact and benefit patients.